We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Oramed Pharmaceuticals Inc (ORMP) Common Stock USD0.012

Sell:$2.15 Buy:$2.26 Change: $0.13 (5.58%)
Market closed |  Prices as at close on 18 April 2024 | Switch to live prices |
Sell:$2.15
Buy:$2.26
Change: $0.13 (5.58%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 18 April 2024 | Switch to live prices |
Sell:$2.15
Buy:$2.26
Change: $0.13 (5.58%)
Market closed |  Prices as at close on 18 April 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Oramed Pharmaceuticals Inc. is a pharmaceutical company engaged in the research and development of pharmaceutical solutions with a technology platform. The Company has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.

Contact details

Address:
1185 AVENUE OF THE AMERICAS, 3RD FLOOR
NEW YORK
10036
United States
Telephone:
+1 (646) 8441164
Website:
https://oramed.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ORMP
ISIN:
US68403P2039
Market cap:
$97.25 million
Shares in issue:
40.52 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Nadav Kidron
    Chairman of the Board, President, Chief Executive Officer
  • David Silberman
    Chief Financial Officer, Treasurer
  • Joshua Hexter
    Chief Operating and Business Officer
  • Miriam Kidron
    Chief Scientific Officer, Director
  • Netanel Derovan
    General Counsel, Company Secretary, Chief Legal Officer
  • Michael Rabinowitz
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.